Philip Sutera

999 total citations
38 papers, 439 citations indexed

About

Philip Sutera is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Philip Sutera has authored 38 papers receiving a total of 439 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Philip Sutera's work include Prostate Cancer Treatment and Research (20 papers), Prostate Cancer Diagnosis and Treatment (12 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Philip Sutera is often cited by papers focused on Prostate Cancer Treatment and Research (20 papers), Prostate Cancer Diagnosis and Treatment (12 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Philip Sutera collaborates with scholars based in United States, Türkiye and Belgium. Philip Sutera's co-authors include Joshua N. Kolev, Ritesh Singh, Rudi Fasan, Dwight E. Heron, Steven A. Burton, Ian F. Pollack, Daniel R. Premkumar, Hong Wang, Mark E. Bernard and Ronny Kalash and has published in prestigious journals such as Journal of Clinical Oncology, ACS Catalysis and Clinical Cancer Research.

In The Last Decade

Philip Sutera

32 papers receiving 436 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philip Sutera United States 10 147 133 114 100 66 38 439
Neeraj Rastogi India 16 114 0.8× 120 0.9× 82 0.7× 207 2.1× 82 1.2× 41 578
Sarah Lowndes United Kingdom 7 157 1.1× 90 0.7× 48 0.4× 114 1.1× 28 0.4× 10 455
Jonas Malmquist Sweden 12 434 3.0× 496 3.7× 59 0.5× 187 1.9× 45 0.7× 28 825
Donna J. Affleck United States 15 141 1.0× 75 0.6× 40 0.4× 127 1.3× 84 1.3× 29 542
Ephraim E. Parent United States 13 61 0.4× 214 1.6× 53 0.5× 51 0.5× 48 0.7× 47 465
Mohammad B. Haskali Australia 12 104 0.7× 77 0.6× 78 0.7× 106 1.1× 14 0.2× 39 380
Eman A. Akam United States 11 98 0.7× 43 0.3× 38 0.3× 92 0.9× 38 0.6× 22 342
Allen Mo United States 10 126 0.9× 48 0.4× 203 1.8× 123 1.2× 75 1.1× 26 525
Antonio Serafín South Africa 11 115 0.8× 94 0.7× 57 0.5× 175 1.8× 68 1.0× 39 357
Peter J. Jessup Australia 12 106 0.7× 61 0.5× 231 2.0× 111 1.1× 38 0.6× 23 468

Countries citing papers authored by Philip Sutera

Since Specialization
Citations

This map shows the geographic impact of Philip Sutera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Sutera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Sutera more than expected).

Fields of papers citing papers by Philip Sutera

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Sutera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Sutera. The network helps show where Philip Sutera may publish in the future.

Co-authorship network of co-authors of Philip Sutera

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Sutera. A scholar is included among the top collaborators of Philip Sutera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Sutera. Philip Sutera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Andrews, Jack R., Aurélie De Bruycker, Ryan Phillips, et al.. (2025). PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts. Clinical Cancer Research. 31(6). 1142–1149. 5 indexed citations
3.
Sutera, Philip, Matthew P. Deek, Adrianna A. Mendes, et al.. (2024). Validation of a Digital Pathology-Based Multimodal Artificial Intelligence Model in Oligometastatic Castration-Sensitive Prostate Cancer, including in Patients from the STOMP and ORIOLE Phase II Randomized Clinical Trials. International Journal of Radiation Oncology*Biology*Physics. 120(2). S133–S133.
4.
Önal, Cem, et al.. (2024). Impact of Definitive Radiotherapy on Metabolic Response Measured with 68Ga-PSMA-PET/CT in Patients with Intermediate-Risk Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 120(2). e570–e571. 1 indexed citations
5.
Sutera, Philip, Jongmyung Kim, Ritesh Kumar, et al.. (2024). PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer. The Prostate. 84(14). 1301–1308. 2 indexed citations
6.
7.
8.
Sutera, Philip, Amol C. Shetty, Yang Song, et al.. (2023). Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer. European Urology Oncology. 7(2). 241–247. 6 indexed citations
9.
Sutera, Philip, et al.. (2023). PSMA-Positive Extracellular Vesicles Predict Disease Recurrence in Oligometastatic Castration-Sensitive Prostate Cancer Treated with Stereotactic Ablative Radiotherapy: Analysis of the ORIOLE trial. International Journal of Radiation Oncology*Biology*Physics. 117(2). S36–S36. 1 indexed citations
10.
Rana, Zaker, Jason K. Molitoris, Matthew J. Ferris, et al.. (2023). Phase 2 randomized total eradication of metastatic lesions following definitive radiation to the prostate in de novo oligometastatic prostate cancer (TERPs) trial.. Journal of Clinical Oncology. 41(6_suppl). TPS275–TPS275. 1 indexed citations
11.
Sutera, Philip, Amol C. Shetty, Yang Song, et al.. (2023). Identification of a Predictive Genomic Biomarker for Prostate Directed Therapy in Synchronous Low-Volume Metastatic Castration Sensitive Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 117(2). e441–e442.
12.
Sutera, Philip, Heath D. Skinner, Matthew E. Witek, et al.. (2023). Histology Specific Molecular Biomarkers: Ushering in a New Era of Precision Radiation Oncology. Seminars in Radiation Oncology. 33(3). 232–242. 2 indexed citations
13.
Sutera, Philip, Rodney E. Wegner, Stephen Abel, et al.. (2020). Post-Operative Morbidity and Mortality Following Total Neoadjuvant Therapy Versus Conventional Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Journal of Gastrointestinal Cancer. 52(3). 976–982. 3 indexed citations
14.
Ling, Diane C., Philip Sutera, Emilia J. Diego, et al.. (2019). Is Multifocal Regression a Risk Factor for Ipsilateral Breast Tumor Recurrence in the Modern Era After Neoadjuvant Chemotherapy and Breast Conservation Therapy?. International Journal of Radiation Oncology*Biology*Physics. 104(4). 869–876. 15 indexed citations
15.
Sutera, Philip, Ronny Kalash, D.A. Clump, et al.. (2018). Stereotactic Ablative Radiation Therapy for Unresectable Colorectal Oligometastases. Advances in Radiation Oncology. 4(1). 57–62. 8 indexed citations
16.
Bernard, Mark E., Philip Sutera, Steven A. Burton, et al.. (2018). Initial Results of a Prospective Study of Adjuvant Pancreatic Stereotactic Body Radiation Therapy for Close or Positive Margins. Advances in Radiation Oncology. 4(2). 294–301. 9 indexed citations
17.
18.
Sutera, Philip, Mark E. Bernard, Beant S. Gill, et al.. (2017). One- vs. Three-Fraction Pancreatic Stereotactic Body Radiation Therapy for Pancreatic Carcinoma: Single Institution Retrospective Review. Frontiers in Oncology. 7. 272–272. 9 indexed citations
19.
Jane, Esther P., et al.. (2016). Survivin inhibitor YM155 induces mitochondrial dysfunction, autophagy, DNA damage and apoptosis in Bcl‐xL silenced glioma cell lines. Molecular Carcinogenesis. 56(4). 1251–1265. 33 indexed citations
20.
Premkumar, Daniel R., et al.. (2016). Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737–Mediated Cell Death in Malignant Human Glioma Cell Lines. Journal of Pharmacology and Experimental Therapeutics. 356(2). 354–365. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Neeraj Rastogi Breakdown of academic impact, for papers by Sarah Lowndes Breakdown of academic impact, for papers by Jonas Malmquist Breakdown of academic impact, for papers by Donna J. Affleck Breakdown of academic impact, for papers by Ephraim E. Parent Breakdown of academic impact, for papers by Mohammad B. Haskali Breakdown of academic impact, for papers by Eman A. Akam Breakdown of academic impact, for papers by Allen Mo Breakdown of academic impact, for papers by Antonio Serafín Breakdown of academic impact, for papers by Peter J. Jessup
Rankless by CCL
2026